No discernible effect of high-dose 5-HT_2AR blockade on error rates in the reward-size task. by Yukiko Hori (299784)

Analysis of ATP1A1 protein expression, blood pressure, heart rate and activity in heterozygous <i>ATP1A1^+/−</i> and wild-type male mice. by Victoria L. Herrera (383897)

“…(B) Densitometry analysis of samples shown in (A) detecting 58% decrease ATP1A1 levels in <i>ATP1A1^+/−</i> kidneys. …”

A set of 5 criteria for the needs of multi-criteria evaluation–combination A. by Roman Vavrek (13200141)

Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

“…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …”

Evaluating the Reduced Hydrophobic Taste Sensor Response of Dipeptides by Theasinensin A by Using NMR and Quantum Mechanical Analyses by Jian Guo (191157)

“…Quantum mechanical calculations and rotating frame nuclear Overhauser effect-NMR spectroscopy provided configuration information on the geometry of the complex that Trp-Leu formed with TSA (1:1 complex) with a Δ<i>G</i> energy of –8.7 kJ/mol. A sensor analysis using artificial-lipid membranes demonstrated that the changes in membrane potential of 1 mM Trp-Leu (21.8 ± 1.3 mV) and Leu-Trp (5.3 ± 0.9 mV) were significantly (<i>P</i> < 0.001) reduced by 1 mM TSA (Trp-Leu, 13.1 ± 2.4 mV; Leu-Trp, 3.5 ± 0.5 mV; TSA alone, 0.2 ± 0.01 mV), indicating the effective suppression of hydrophobicity of dipeptides by TSA-formed complex.…”

S5 Raw images - by Mitsunori Miyazaki (197902)

Knockdown of PODXL expression correlates with decreased cell proliferation. by Zev A. Binder (471251)

Octanoic acid challenge decreases the intracellular pH. by Liam A. Royce (529244)

Decreasing pixel differences caused by worm movement correspond to decreasing locomotive health. by Areta Jushaj (8525655)

The effects of pretreatment with fingolimod-phosphate on BMECs in the presence of MS sera. by Hideaki Nishihara (545149)

“…Pretreatment with fingolimod-phosphate resulted in an increase in the claudin-5 protein levels (B) and TEER values (G) and a decrease in the VCAM-1 protein levels (F) in the BMECs, which were upregulated after exposure to the sera from all MS patients, including the RRMS-R, RRMS-S and SPMS patients, compared to that observed in the cells not pretreated with fingolimod-phosphate.…”

Clinical characteristics. by Jesse A. Davidson (3158913)

13C5-adenosine production with ex vivo alkaline phosphatase supplementation. by Jesse A. Davidson (3158913)

Correlation of AP activity to 13C5-adenosine production pre-operation and prior to separation from cardiopulmonary bypass. by Jesse A. Davidson (3158913)

Pre-operation to rewarming change in alkaline phosphatase activity versus change in 13C5-adenosine with CD73 inhibition. by Jesse A. Davidson (3158913)

Pre-operation to rewarming change in alkaline phosphatase activity versus change in 13C5-adenosine without CD73 inhibition. by Jesse A. Davidson (3158913)

13C5-adenosine production without ectonucleotidase inhibition, with CD73 inhibition, and with alkaline phosphatase inhibition. by Jesse A. Davidson (3158913)

Adenosine production with AP supplementation + = significant at the 0.05 level adjusted for multiple comparisons. by Jesse A. Davidson (3158913)

Alkaline Phosphatase, Soluble Extracellular Adenine Nucleotides, and Adenosine Production after Infant Cardiopulmonary Bypass by Jesse A. Davidson (3158913)

“…Inhibition of alkaline phosphatase led to a marked decrease in 13C5-adenosine production (11.9μmol/L vs 2.7μmol/L; p<0.0001). …”

Ratio of 13C5-adenosine production with and without CD73 inhibition, pre-operation and prior to separation from cardiopulmonary bypass. by Jesse A. Davidson (3158913)

RNF5 depletion suppresses PEL xenograft tumor growth and decreases the levels of cell cycle gene expression and hedgehog signaling in tumors. by Xiaojuan Li (351842)